Apollo Hospitals (APOLLOHOSP) Q1 26/27 earnings summary

Executive summary

• Consolidated revenue grew 21% year-on-year to INR 7,043 crores (70,435 mio) in Q1 FY27, with EBITDA up 28% to INR 1,092 crores and PAT up 34% to INR 581 crores, reflecting strong double-digit growth across all business verticals.

• Healthcare Services, Apollo HealthCo, AHLL, Digital Health & Pharmacy Distribution, and Diagnostics & Retail Health all reported robust growth and improved profitability, driven by sustained demand, high-acuity specialties, and operational execution.

• Expansion included commissioning a 180-bed facility in Sarjapur, Bengaluru, five new hospitals, and continued ramp-up of digital and diagnostics platforms.

• Clinical excellence recognized with multiple awards and new AI-driven initiatives across business segments.

• Strategic focus remains on integrated healthcare, capacity expansion, digital transformation, and ongoing restructuring of omni-channel pharmacy and digital health business.

Financial highlights

• Healthcare Services revenue grew 22% year-on-year to INR 3,567 crores (35,670 mio), with EBITDA margin at 24.2% and PAT up 25% to INR 480 crores.

• Apollo HealthCo revenue rose 20% year-on-year to INR 2,977 crores (29,770 mio); EBITDA increased to INR 171 crores; PAT at INR 101 crores; digital cash loss reduced to INR 10 crores.

• AHLL revenue increased 15% year-on-year to INR 499 crores (4,995 mio); EBITDA up 46% to INR 59 crores; diagnostics vertical revenue up 31%.

• Consolidated EBITDA reached INR 1,092 crores (10,920 mio) with a 15.5% margin; PAT was INR 581 crores (5,805 mio), up 34% year-on-year.

• Digital cash loss reduced to INR 10 crores (97 mio) for the quarter, excluding ESOP charges.

Outlook and guidance

• On track to deliver 20% revenue growth in hospitals for FY27, with established hospitals expected to grow at 13%-14% and new hospitals adding 7%.

• Margin for established hospitals expected to sustain at 26%, with further cost optimization possible.

• Digital vertical and insurance business expected to break even by Q3 FY27.

• Expansion plans to increase bed capacity to 14,100 by FY31, funded largely from internal accruals.

• Expectation to achieve INR 250 bn annualized revenue run rate in Q4 FY27, with EBITDA margin in the 6.5%-7.0% range for the proposed NewCo.